Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed...

Rasan Information Technology Company (Tadawul: 8313), the leading Insurtech and Fintech platform in the Kingdom of Saudi Arabia, today announced its financial results for the first quarter of 2026, delivering highest ever quarterly revenue, accelerated profitability, and broad-based growth across all products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504153362/en/Rasan Builds on Momentum Highest-Ever Quarterly Revenue in Q1...